Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review)

International Journal of Oncology

Volumn 47, Issue 4, 2015, Pages 1203-1210

  Subramani, Ramadevi ^a   Gangwani, Laxman ^a   Nandy, Sushmita Bose ^a   Arumugam, Arunkumar ^a   Chattopadhyay, Munmun ^a   Lakshmanaswamy, Rajkumar ^a  

^a USA   (United States)

Author keywords

Biomarker; Diagnosis; MicroRNA; Pancreatic ductal adenocarcinoma; Prognosis; Therapeutics

Indexed keywords

MICRORNA; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; DRUG TARGETING; HUMAN; LIFE EXPECTANCY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; GENETICS; PANCREATIC NEOPLASMS;

BIOMARKERS, TUMOR; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS;

EID: 84940984903     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3129     Document Type: Review

References (75)

1. Moniri MR, Dai LJ and Warnock GL: The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Ther 21: 12-23, 2014.
2. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
3. Michaud DS: Epidemiology of pancreatic cancer. Minerva Chir 59: 99-111, 2004.
4. Tamburrino A, Piro G, Carbone C, Tortora G and Melisi D: Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol 4: 56, 2013.
5. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450, 2003.
6. B urris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
7. Cheng H1, Shi S, Cai X, Long J, Xu J, Liu C and Yu X: microRNA signature for human pancreatic cancer invasion and metastasis. Exp Ther Med 4: 181-187, 2012.
8. Longati P, Jia X, Eimer J, Wagman A, Witt MR, Rehnmark S, Verbeke C, Toftgard R, Löhr M and Heuchel RL: 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 13: 95, 2013. doi: 10.1186/1471-2407-13-95.
9. Qazi AM1, Gruzdyn O, Semaan A, Seward S, Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman DL, et al: Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery 152: 704-711; discussion 711-713, 2012.
10. B orja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ and Vickers SM: Molecular targeted therapies for pancreatic cancer. Am J Surg 196: 430-441, 2008.
11. Dai ZJ, Gao J, Kang HF, Ma YG, Ma XB , Lu WF, Lin S, Ma HB, Wang XJ and Wu WY: Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells. Drug Des Devel Ther 7: 149-159, 2013.
12. Papaconstantinou IG, Lykoudis PM, Gazouli M, Manta A, Polymeneas G and Voros D: A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma. Pancreas 41: 671-677, 2012.
13. X u C, Ping Y, Li X, Zhao H, Wang L, Fan H, Xiao Y and Li X: Prioritizing candidate disease miRNAs by integrating phenotype associations of multiple diseases with matched miRNA and mRNA expression profiles. Mol Biosyst 10: 2800-2809, 2014.
14. Qiu C, Chen G and Cui Q: Towards the understanding of microRNA and environmental factor interactions and their relationships to human diseases. Sci Rep 2: 318, 2012.
15. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12 body fluids. Clin Chem 56: 1733-1741, 2010.
16. Humeau M, Torrisani J and Cordelier P: miRNA in clinical practice: Pancreatic cancer. Clin Biochem 46: 933-936, 2013.
17. Vlastos G and Verkooijen HM: Minimally invasive approaches for diagnosis and treatment of early-stage breast cancer. Oncologist 12: 1-10, 2007.
18. Sicard F, Gayral M, Lulka H, Buscail L and Cordelier P: Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther 21: 986-994, 2013.
19. Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu P, Wei J, Jiang K and Miao Y: miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Oncol Rep 29: 1769-1776, 2013.
20. K awaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, et al: Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 108: 361-369, 2013.
21. Wang WS, Liu LX, Li GP, Chen Y, Li CY, Jin DY and Wang XL: Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev Res (Phila) 6: 331-338, 2013.
22. Huang J, Egger M, Grizzle W and McNally L: MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells. Biotech Histochem 88: 397-402, 2013.
23. Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J and Ramirez J: miR-34a as a prognostic marker of relapse in surgically resected nonsmall-cell lung cancer. Carcinogenesis 30: 1903-1909, 2009.
24. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z and Liu L: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 33: 514-524, 2013.
25. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and Chen J: The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 31: 1726-1733, 2010.
26. Delpu Y, Lulka H, Sicard F, Saint-Laurent N, Lopez F, Hanoun N, Buscail L, Cordelier P and Torrisani J: The rescue of miR-148a expression in pancreatic cancer: An inappropriate therapeutic tool. PLoS One 8: e55513, 2013.
27. Druz A, Chen YC, Guha R, Betenbaugh M, Martin SE and Shiloach J: Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines. RNA Biol 10: 287-300, 2013.
28. Hou B, Jian Z, Chen S, Ou Y, Li S and Ou J: Expression of miR-216a in pancreatic cancer and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao 32: 1628-1631, 2012.
29. Jiao LR, Frampton AE, Jacob J, Pellegrino L, Krell J, Giamas G, Tsim N, Vlavianos P, Cohen P, Ahmad R, et al: MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One 7: e32068, 2012.
30. Drakaki A and Iliopoulos D: MicroRNA-gene signaling pathways in pancreatic cancer. Biomed J 36: 200-208, 2013.
31. Wang J and Sen S: MicroRNA functional network in pancreatic cancer: From biology to biomarkers of disease. J Biosci 36: 481-491, 2011.
32. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054, 2007.
33. B loomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM, et al: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908, 2007.
34. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 33: 698-709, 2009.
35. Mees ST, Mardin WA, Wendel C, Baeumer N, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M and Haier J: EP300 - a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer 126: 114-124, 2010.
36. Szafranska AE1, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452, 2007.
37. Szafranska AE1, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, et al: Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 54: 1716-1724, 2008.
38. Zhang S, Cai X, Huang F, Zhong W and Yu Z: Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. Exp Oncol 30: 265-268, 2008.
39. Gironella M1, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et al: Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 104: 16170-16175, 2007.
40. Pawa N, Arulampalam T and Norton JD: Screening for colorectal cancer: Established and emerging modalities. Nat Rev Gastroenterol Hepatol 8: 711-722, 2011.
41. Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB and Park JY: Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J 54: 643-649, 2013.
42. Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W and Kong X: Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131: 683-691, 2012.
43. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM and Sen S: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2: 807-813, 2009.
44. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG and Maitra A: Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 10: 66-73, 2010.
45. Park JY, Helm J, Coppola D, Kim D, Malafa M and Kim SJ: MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol 17: 817-827, 2011.
46. Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, Konishi H, Shiozaki A, Ikoma H, Okamoto K, et al: Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 105: 1733-1740, 2011.
47. K eklikoglou I, Hosaka K, Bender C, Bott A, Koerner C, Mitra D, Will R, Woerner A, Muenstermann E, Wilhelm H, et al: MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene: Dec, 15, 2014. http://dx.doi.org/10.1038/onc.2014.408.
48. Song S and Ajani JA: The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol 10: 109-118, 2013.
49. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT and Maitra A: Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10: 1470-1480, 2011.
50. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT and Maitra A: Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma. Mol Carcinog 53: 711-712, 2013.
51. Liu C, Cheng H, Shi S, Cui X, Yang J, Chen L, Cen P, Cai X, Lu Y, Wu C, et al: MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med 13: 467-478, 2013.
52. MacKenzie TN, Mujumdar N, Banerjee S, Sangwan V, Sarver A, Vickers S, Subramanian S and Saluja AK: Triptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol Cancer Ther 12: 1266-1275, 2013.
53. Sun T, Kong X, Du Y and Li Z: Aberrant MicroRNAs in pancreatic cancer: Researches and clinical implications. Gastroenterol Res Pract 2014: 386561, 2014.
54. Di Leva G and Croce CM: miRNA profiling of cancer. Curr Opin Genet Dev 23: 3-11, 2013.
55. K ong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, Jing Q, Qin Y and Li Z: Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci 56: 602-609, 2011.
56. Frampton AE, Krell J, Jacob J, Stebbing J, Jiao LR and Castellano L: microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther 11: 1837-42, 2011.
57. Mardin WA and Mees ST: MicroRNAs: Novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Ann Surg Oncol 16: 3183-9, 2009.
58. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G and Voros D: Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 42: 67-71, 2013.
59. Schultz NA, Andersen KK , Roslind A, Willenbrock H, Wojdemann M and Johansen JS: Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer-five microRNAs in a prognostic index. World J Surg 36: 2699-2707, 2012.
60. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, et al: MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70: 4528-4538, 2010.
61. B auer AS, Keller A, Costello E, Greenhalf W, Bier M, Borries A, Beier M, Neoptolemos J, Büchler M, Werner J, et al: Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One 7: e34151, 2012.
62. Costello E, Greenhalf W and Neoptolemos JP: New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9: 435-444, 2012.
63. Giovannetti E1, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, et al: Highthroughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One 7: e49145, 2012.
64. Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF and Korc M: MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 17: 5812-5821, 2011.
65. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA and Sarkar FH: Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70: 3606-3617, 2010.
66. Yu J1, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, Nakata K and Tanaka M: MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 9: 169, 2010.
67. Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, Ueda J, Nagai E, Hashizume M and Tanaka M: MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol 18: 2381-2387, 2011.
68. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P and Taubert H: Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 126: 73-80, 2010.
69. Hasegawa S, Eguchi H, Nagano H, Konno M, Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, et al: MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer 111: 1572-1580, 2014.
70. Paik WH, Kim HR, Park JK, Song BJ, Lee SH and Hwang JH: Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res 33: 1473-1481, 2013.
71. B itarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P and Garcia-Foncillas J: MicroRNA-451 is involved in the selfrenewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29: 1661-1671, 2011.
72. Tan L, Sui X, Deng H and Ding M: Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. PLoS One 6: e23383, 2011.
73. Mazur PK and Siveke JT: Genetically engineered mouse models of pancreatic cancer: Unravelling tumour biology and progressing translational oncology. Gut 61: 1488-1500, 2012.
74. Choi SY, Lin D, Gout PW, Collins CC, Xu Y and Wang Y: Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev 79-80: 222-237, 2014.
75. Mazur PK, Herner A, Neff F and Siveke JT: Current methods in mouse models of pancreatic cancer. Methods Mol Biol 1267: 185-215, 2015.